Ufp Technologies Stock Earnings Reports

UFP Technologies reported a solid start to 2026 with total revenue up 4.1% and medical sales up 5.9%, driven by strength in robotic surgery, patient surfaces & support, and interventional & surgical segments. The company launched four large programs (three brand-new) that are in early ramp stages, with three customers already requesting double capacity; management expects these programs to become meaningful contributors in the second half of the year. Nonmedical sales declined (notably automotive as UFP phases out that market) and wound care was temporarily soft due to two customers reducing orders while they work through excess inventory. EPS growth lagged revenue due to start-up costs for the new programs, labor inefficiencies at AJR following a verification process, and nonrecurring legal expenses tied to a cyberattack and CEO transition. Gross margin improved slightly to 28.8% despite AJR inefficiencies; adjusted operating margin was 16.7% and adjusted diluted EPS was $2.48. The company is expanding capacity with two new buildings in Santiago and La Romana (DR) and is planning APAC capacity additions. Tariff reductions may help margins, although raw material inflation from oil-price volatility related to the Iran conflict is a headwind that management expects to pass through to customers. Cash from operations was $3.2M in Q1; capital expenditures were $1.7M and leverage was ~1.14x after ~$4M of debt paydown since quarter end. Management remains disciplined on M&A, pursuing targeted opportunities and viewing acquisitions as a significant component of long-term growth. CEO transition: Jeff Bailly will step down in June and Mitch Rock will become CEO; Bailly will remain Executive Chair for a year to support the transition.